<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seven patients with a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or "smoldering" <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> were treated with <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> in low dosage </plain></SENT>
<SENT sid="1" pm="."><plain>Four patients experienced transient, partial responses characterized by improved peripheral blood counts, cessation of transfusion requirements, and a decreased incidence of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment was associated with significant, transient hematologic toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>The appropriate clinical role of low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> remains uncertain </plain></SENT>
</text></document>